Campbell & CO Investment Adviser LLC Lowers Holdings in Edgewise Therapeutics, Inc. $EWTX

Campbell & CO Investment Adviser LLC trimmed its stake in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) by 90.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,140 shares of the company’s stock after selling 103,041 shares during the quarter. Campbell & CO Investment Adviser LLC’s holdings in Edgewise Therapeutics were worth $181,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC purchased a new position in shares of Edgewise Therapeutics in the 3rd quarter worth about $160,000. HighMark Wealth Management LLC increased its stake in Edgewise Therapeutics by 2.1% during the 3rd quarter. HighMark Wealth Management LLC now owns 53,179 shares of the company’s stock valued at $863,000 after purchasing an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Edgewise Therapeutics by 11.2% in the second quarter. China Universal Asset Management Co. Ltd. now owns 21,120 shares of the company’s stock worth $277,000 after buying an additional 2,127 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Edgewise Therapeutics by 14.9% in the second quarter. Tower Research Capital LLC TRC now owns 9,148 shares of the company’s stock worth $120,000 after buying an additional 1,188 shares in the last quarter. Finally, Exome Asset Management LLC lifted its stake in shares of Edgewise Therapeutics by 74.2% in the second quarter. Exome Asset Management LLC now owns 124,470 shares of the company’s stock worth $1,632,000 after buying an additional 53,032 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Wedbush reduced their price target on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, November 7th. JPMorgan Chase & Co. lifted their target price on Edgewise Therapeutics from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Wall Street Zen upgraded Edgewise Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edgewise Therapeutics in a report on Wednesday. Finally, Royal Bank Of Canada lifted their price objective on Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.67.

Edgewise Therapeutics Price Performance

Shares of EWTX opened at $28.61 on Friday. The firm has a market capitalization of $3.03 billion, a P/E ratio of -18.11 and a beta of 0.27. Edgewise Therapeutics, Inc. has a one year low of $10.60 and a one year high of $30.48. The business has a fifty day moving average of $24.62 and a 200 day moving average of $18.46.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.01. Analysts expect that Edgewise Therapeutics, Inc. will post -1.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jonathan C. Fox bought 10,700 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were bought at an average cost of $18.64 per share, for a total transaction of $199,448.00. Following the completion of the transaction, the director owned 23,702 shares of the company’s stock, valued at approximately $441,805.28. This trade represents a 82.30% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alan J. Russell sold 100,000 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $21.12, for a total value of $2,112,000.00. Following the sale, the insider directly owned 23,400 shares of the company’s stock, valued at $494,208. This represents a 81.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 23.20% of the stock is currently owned by insiders.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.